Abstract
Despite the recent advances in the management of cervical cancer using cisplatin-based concurrent chemoradiotherapy, substantial treatment failure still occurs, especially in advanced-stage patients and early-stage cervical cancer patients with high-risk prognostic factors. Therefore, efforts to further improve the survival and quality of life of these patients are necessary. Nedaplatin (cis-diammine-glycoplatinum), a derivative of cisplatin, was developed with the aim of producing a treatment with a similar effectiveness to cisplatin but decreased renal and gastrointestinal toxicities. Based on the promising results of preclinical studies, the clinical efficacy of nedaplatin as a radiosensitizing agent was evaluated in patients with cervical cancer. Retrospective analysis of nedaplatin-based concurrent chemoradiotherapy (CCRT) against cervical cancer suggested that nedaplatin-based CCRT can be considered as an alternative to cisplatin-based CCRT in both early-stage and advanced-stage cervical cancer patients. However, due to the lack of a randomized controlled study, nedaplatin-based CCRT has not been convincingly proven to be clinically effective in patients with cervical cancer. Further investigations in randomized controlled trials are therefore needed.
Highlights
Nedaplatin, a derivative of cisplatin, was developed in 1983 by Shionogi Pharmaceutical Company in Japan with the aim of producing a treatment with a similar effectiveness to cisplatin but decreased renal and gastrointestinal toxicities [1]
We show the results of these retrospective analyses and provide information on the results of other clinical studies that investigated the efficacy of nedaplatin-based concurrent chemoradiotherapy (CCRT) in patients with cervical cancer
We retrospectively evaluated the effectiveness of nedaplatin-based CCRT in 145 Japanese patients with FIGO Stage IA2-IIB cervical cancer after radical hysterectomy and pelvic lymphadenectomy [18]
Summary
Nedaplatin (cis-diammine-glycoplatinum), a derivative of cisplatin, was developed in 1983 by Shionogi Pharmaceutical Company in Japan with the aim of producing a treatment with a similar effectiveness to cisplatin but decreased renal and gastrointestinal toxicities [1]. They were retrospective in nature, to the best of our knowledge, these are the only reports that have demonstrated a significant improvement in the survival of cervical cancer patients treated with nedaplatin-based CCRT. In early-stage cervical cancer patients demonstrating high-risk prognostic factors, a prospective randomized clinical trial (GOG 109/SWOG 87-97) examined the role of adjuvant cisplatin-based CCRT after radical hysterectomy and pelvic lymphadenectomy [41].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have